Table 1.
Main characteristics of studies included in the meta-analysis of incidence and mortality of renal cell carcinoma (RCC) after kidney transplantation (KTx) [11,12,13,14,15,16,17,18,19,20,23,28,29,30,31,32,33,34,35,36,38,39].
| Study | Year | Type of Study | Number of Patients | Incidence of RCC | Follow-Up Time after Transplant | Time from Transplant to Cancer Diagnosis | Mortality of RCC | Quality Assessment |
|---|---|---|---|---|---|---|---|---|
| Hoshida et al. [11] | 1997 | Cohort | 1744 | 15/1744 | N/A | N/A | N/A | S4 C0 O3 |
| Agraharkar et al. [12] | 2004 | Cohort | 1739 | 6/1739 | Mean 6.1 years | N/A | N/A | S4 C1 O3 |
| Neuzillet et al. [13] | 2004 | Cohort | 933 | 11/933 | N/A | Mean 70.9 ± 49.4 (range 8–156) months | 2/11 (1 died due to cancer) | S4 C0 O2 |
| Moudouni et al. [14] | 2006 | Cohort | 373 | 10/373 | N/A | Mean 12.8 years Median 127 in patients treated with cyclosporine A and 114 months in patients not treated with cyclosporine A |
1/10 (1 died due to cancer) | S4 C0 O3 |
| Ianhez et al. [39] | 2007 | Cohort | 1375 | 10/1375 9 in native kidney 1 in allograft kidney |
N/A | N/A | 3/10 (2 died due to myocardial infarction and one due to penile cancer) | S4 C0 O2 |
| Schwarz et al. [38] | 2007 | Cohort | 561 | 8/561 7 de novo in native kidney 1 de novo in allograft kidney |
N/A | 105.2 ± 62.39 months | N/A | S4C2O3 |
| Tsai et al. [15] | 2008 | Cohort | 3259 | Touring group 15/215 kidney cancer Domestic group 4/321 kidney cancer |
Touring group Mean 76.2 ± 48.1 months Domestic group Mean 81.5 ± 53.4 months |
N/A | N/A | S4 C1 O3 |
| Filocamo et al. [16] | 2009 | cohort | 694 | Native de novo 10/694 |
N/A | 61.8 months (12–156 months) | 3/10 (3 died due to cancer other than RCC) | S4 C1 O3 |
| Leveridge et al. [17] | 2010 | cohort | 3568 | 39/3568 native kidney 8/3568 allograft kidney |
6.6 years | Native 10.6 years allograft 12.1 years |
5 native died (not RCC cause), 1 allograft died due to cardiac cause | S4 C0 O3 |
| Hwang et al. [18] | 2011 | Cohort | 1695 | 7/1695 | 9.1 ± 6.9 years | Mean 11.8 ± 6.0 years | N/A | S4 C0 O3 |
| Lee et al. [28] | 2011 | Cohort | 2757 | 21/2757 | N/A | Mean 119 (range 0–264) months | N/A | S4 C1 O2 |
| Ploussard et al. [20] | 2012 | Cohort | 2396 | Allograft kidney 12/2396 |
N/A | Mean 13 (range 4–20) years | 0/12 | S4 C0 O3 |
| Einollahi et al. [29] | 2012 | Cohort | 12,525 | 6/12,525 | N/A | Median 16 months | N/A | S4 C0 O3 |
| Gigante et al. [30] | 2012 | Cohort | 213 | N/A | N/A | Mean 91 ± 82 months | 6/213 due to RCC | S4 C0 O2 |
| Tillou et al. [19] | 2012 | Cohort | 41,806 | Allograft kidney 79/41,806 |
N/A | Mean 131.7 (0.9–244) months | 4/79 | S4 C0 O3 |
| Cheung et al. [31] | 2012 | Cohort | 4895 | 26/4895 | N/A | Median 4 (0.2–16.5) years | N/A | S4 C1 O3 |
| Piselli et al. [32] | 2013 | Cohort | 7217 | 31/7217 | Median 5.2 years (2.9–7.8) | N/A | N/A | S4 C1 O3 |
| Ryosaka et al. [33] | 2015 | Cohort | 202 | N/A | N/A | N/A | Solid-type renal cell carcinoma 2/17 Cystic-type renal cell carcinoma 2/27 |
S4 C0 O3 |
| Kalil et al. [34] | 2015 | Cohort | 115,845 | Primary kidney transplant 514/109,224 Retransplant 43/6621 |
Mean 1st–4.6 years 2nd–3.7 years 3rd–2.9 years 4th–3.4 years |
N/A | N/A | S4 C2 O3 |
| Karami et al. [35] | 2016 | Cohort | 116,208 | 683/116,208 | Median 4.2 years (range 0.003–23.1) | N/A | N/A | S4 C0 O2 |
| Takagi et al. [36] | 2017 | Cohort | 42 | N/A | N/A | Mean 86 ± 69 months | 9/42 (5 died due to cancer) | S4 C0 O3 |
| Cognard et al. [23] | 2018 | Cohort | 143 with history of pre-transplant kidney cancer | 13/143 | Mean 5.6 ± 3.2 years | Mean 3 ± 2.3 years (range 45 days–7 years) | 10/13 (9 died due to cancer) | S4 C0 O3 |
KTx, kidney transplantation; N/A, not available; RCC, renal cell carcinoma; S, C, O, selection, comparability, and outcome.